Home
overview

This conference has already taken place.  For information on the 2010 event, please click on the link below:

 

COPD: Novel Therapeutics and Management Strategies 2010

 


For information about the 2009 Asthma & COPD conference, please see below...

 

“…..found this year’s to be especially timely information and the networking also quite helpful.  Definitely worth the trip.”

Scott Fleming, Senior Vice President, Microdose Technologies Inc

 

With 300 million people in the world estimated to be suffering from asthma, and COPD predicted to become the third largest killer worldwide by 2020, the market for drugs in these areas is huge. 

 

SMi’s 5th annual conference on Asthma & COPD will bring together industry experts in respiratory medicine and drug discovery, providing a unique opportunity to discuss the future for asthma & COPD therapeutics.  Presentations addressing regulatory challenges in the area will help streamline your drug development process and a look at the issues involved in paediatric asthma therapeutics will help with the ever growing child market in asthma.

 
 
 
 
Hear presentations from industry leaders on:          
   

 

  • New therapeutics
  • Regulatory challenges in Asthma & COPD
  • Paediatric Asthma and associated therapeutics challenges
  • Inhaled drug delivery
  • Methodology of clinical trials
   
                                                                                
 
GAIN a valuable insight into the current developments in respiratory medicine
IDENTIFY key areas for the development of new drugs
REVIEW current regulatory issues within respiratory drug development
EXAMINE options for the improvement of clinical trial data
HEAR the approaches taken by top experts in Asthma & COPD research
    This year's delegates include:
 
  • Founder, Chief Scientific Officer & Head, Research & Development, Actimis
  • Chief Executive Officer, Activaero
  • Managing Director, Activaero
  • CMO, Altair Therapeutics
  • Associate Professor Research Physician, Astrazeneca R & D Lund
  • Marketing Assistant, Bedfont Scientific
  • Vice President, Boehringer Ingelheim
  • Research & Development, Boehringer Ingelheim
  • Medical Adviser, Boehringer Ingelheim
  • Senior Scientific Adviser, Boehringer Ingelheim
  • Director Marketing, Cardinal Health Research Services
  • Medical Expert, Chiesi Farmaceutici
  • Vice President, Clinical Affairs, Deepbreeze
  • National Sales Manager, Fisher & Paykel Helathcare
  • Product Manager, Fisher & Paykel Helathcare
  • Senior Regulatory Scientist, Glaxo Wellcome
  • New Products Manager, Laboratorios Almirall
    • Regulatory Affairs Manager, Merck Sharp & Dohme
    • Senior Vice President, MicroDose Technologies
    • Brand Manager, Napp Pharmaceuticals
    • Senior Brand Manager, Napp Pharmaceuticals
    • Director,  Nspire Health
    • Director Clinical Solutions, Europe, Nspire Health
    • Medical Director, Nycomed
    • Senior Scientist, Nycomed
    • Director Of Project Development, Orion Clincial Services
    • Director, Facilities for Systems Biology & Applications, Pacific Northwest National Laboratory
    • Associate Director, Sepracor
    • Chief Medical Officer, Syntaxin
    • Clinical Research Scientist, Syntaxin
    • Development Director, Vectura
    • BD Executive, Vitalograph
    • Director, Vitalograph
    • Product & Technology Discovery, Manager, Zambon Spa
This conference is an unmissable opportunity to raise the profile of your company amongst the market leaders in this area.
 
 
For speaker opportunities please contact Rachel Francis on +44 (0)20 7827 6056 or email rfrancis@smi-online.co.uk
 
For sponsorship opportunities please contact Alia Malick on +44 (0)20 7827 6168 or email amalick@smi-online.co.uk

Conference programme

8:30 Registration & Coffee

9:00 Chairman's Opening Remarks

Peter Barnes

Peter Barnes, Professor of Thoracic Medicine, Imperial College

9:10 OVERVIEW

Peter Barnes

Peter Barnes, Professor of Thoracic Medicine, Imperial College

  • Asthma and COPD are growing global therapeutic markets
  • There is a need for new treatments for severe asthma which is poorly controlled on current therapy
  • There is a need to find novel anti-inflammatory drugs to treat COPD to reduce exacerbations, disease progression and mortality
  • There is a need to develop therapies that also that COPD co-morbidities
  • 9:50 INHALED DRUG DELIVERY

    Gerhard Scheuch

    Gerhard Scheuch, Chief Executive Officer, Activaero

  • Current technology on the market
  • Problems associated with the current dry powders
  • Improvements which would benefit delivery
  • Nanotechnology in pulmonary drug delivery
  • 10:30 Morning Coffee

    11:00 NEW ASTHMA THERAPEUTICS

    Clive Page

    Clive Page, Professor of Pharmacology, Director of Sackler Institute of Pulmonary Pharmacology, King's College London, and Chairman,, Verona Pharma

  • Mechanism of action
  • Target market for drug
  • Early trial results
  • Hopes for the future
  • 11:40 PAEDIATRIC ASTHMA

    Fadi Eskandar

    Fadi Eskandar, Principal Scientist, Novartis Pharmaceuticals

  • Paediatric inhalation: a therapeutic gap
  • Current Asthma treatment options for children
  • Challenges in developing inhalation therapy for children
  • Implications of EMEA guidelines on paediatric drugs
  • Future perspective for developing paediatric inhalation products
  • 12:20 Networking Lunch

    13:50 ALTERNATIVES TO INHALED DRUGS

    Thomas Eichholtz

    Thomas Eichholtz, Director of Discovery Medicine, AstraZeneca

  • Rationale for use of systemic delivery of drugs for asthma and COPD
  • Current approaches
  • 14:30 OVERCOMING THE CHALLENGES OF INHALER USE IN CHILDREN (AND ELDERLY) WITH AN ACTIVE DPI

    Scott Fleming

    Scott Fleming, Senior Vice President, Sales and Marketing, MicroDose Technologies

  • Obstacles to effective inhaler use in challenging populations
  • Design of the ideal inhaler
  • Benefits of ‘active’ aerosol generation and visual feedback
  • Focus group study results
  • Future improvements
  • 15:10 Afternoon Tea

    15:40 COPD DRUG DEVELOPMENT

    Magnus Korsgren

    Magnus Korsgren, Disease Area Medical Leader, Astrazeneca

     

  • Charactersitics of human LPS challenge models
  • Does LPS challenge induce inflammatory airway responses mimicking characteristics of COPD?
  • Which classes of drug candidates are suitable to explore in LPS challenge models?
  • LPS challenge - pros and cons
  •  
  • 16:20 MEETING THE UNMET NEED IN ASTHMA AND COPD

    Tim Higenbottam

    Tim Higenbottam, Head of Corporate Clinical Development, Chiesi Farmaceutici

  • Chiesi is committed to delivering treatments that fulfil the major unmet needs in COPD and Asthma
  • The clinical studies need to focus on the those aspects of these diseases which are currently not met with existing treatments
  • There is a need to develop not only new measurements that reflect the patients perceptions of their disease as with Patient Reported Outcomes (PRO) but also new study designs that reflect the real disease
  • This can be illustrated by the use of the EXACT PRO a new tool development to detect and quantify exacerbations in COPD
  • The study design is to consider timing studies of exacerbations of COPD to the critical times of the year when the events occur
  • Details of these approaches will be described and the arguments in favour of change advanced
     
  • 17:00 Chairman’s Closing Remarks and Close of Day One

    8:30 Registration & Coffee

    9:00 Chairman's Opening Remarks

    Sebastian Johnston

    Sebastian Johnston, Professor of Adult Respiratory Medicine, Imperial College School of Medicine (N.H.L.I.)

    9:10 COPD TREATMENT

    Matthew Catley

    Matthew Catley, Senior Scientist, U C B Celltech

  • The relevance of current pre-clinical models
  • Clinical trials of biologicals in COPD
  • Potential targets for biologicals in COPD
  • Patient stratification
  • 9:50 DIFFERENTIATED LUNG FUNCTION TESTING IN COPD

    Hans-Juergen Smith

    Hans-Juergen Smith, Product Manager, Cardinal Health

  • Additional methods beside spirometry?
  • Tidal breathing analysis vs. forced spirometry
  • Aspects of peripheral airways obstruction
  • Small airways disease
  • 10:30 Morning Coffee

    11:00 VRIxp™ FUNCTIONAL IMAGING - ASSESSING THERAPEUTIC RESPONSE WITHIN THE LUNGS

    Merav Gat

    Merav Gat, Vice President, Clinical Affairs, Deepbreeze

  • Vibration Response Imaging Technology and Simplicity in Obtaining Lung Data Measurements
  • VRIxp™ image assessment and reproducibility
  • Regional lung functionality to evaluate therapeutic response in Asthma/COPD management
  • Unique approach to differentiate Asthma from COPD
  • 11:40 ACUTE EXACERBATIONS

    Sebastian Johnston

    Sebastian Johnston, Professor of Adult Respiratory Medicine, Imperial College School of Medicine (N.H.L.I.)

  • Triggers of acute exacerbations
  • Mechanisms of exacerbations
  • Experimental models of exacerbations
  • Novel approaches to treatment/prevention of exacerbations
  • 12:20 METHODOLOGY OF CLINICAL TRIALS

    Aleck Harrison

    Aleck Harrison, Consultant Clinical Scientist, AJH Partners

  • Asthma and COPD diagnosis and  definitions for CTs
  • Recording exacerbations electronically
  • Difficulties in obtaining meaningful data
  • E-spirometric diary compliance
  • 13:00 Networking Lunch

    14:00 CASE STUDY

    Mark Parry-Billings

    Mark Parry-Billings, Chief Executive Officer, Topigen Pharmaceuticals

  • Oligonucleotide therapeutics in respiratory disease
  • Rationale for using a multitarget approach in asthma and COPD
  • Design and pre-clinical screening of effective drug candidates
  • Clinical positioning and findings
  • 14:40 COPD DRUG DEVELOPMENT

    Phillip Monk

    Phillip Monk, Head of Development, Synairgen

  • Antiviral therapies in development targeting virus induced exacerbations in asthma and COPD
  • Background data supporting development of inhaled interferon beta
  • Clinical Development Strategy to PoC in asthma and COPD
  • Review of clinical data generated to date including biomarkers               
  • 15:20 Afternoon Tea

    15:50 OPTIFLOW NASAL HIGH FLOW

    Derek Bell

    Derek Bell, Chair in Acute Medicine, Imperial College Faculty of Medicine

  • Non-invasive ventilation
  • High flow therapies
  • Current evidence for potential role in Asthma & COPD management
  • 16:30 IMPROVING THE MANAGEMENT OF ASTHMA

    Keith Allan

    Keith Allan, Head of Global Advocacy, Novartis International

  • Where improvements in current therapies need to be made
  • Expectations of drugs entering trials at the moment
  • Anticipated development hurdles in the future
  • 17:10 Chairman’s Closing Remarks and Close of Conference

    +

    Workshops

    Biomarkers in Asthma & COPD
    Workshop

    Biomarkers in Asthma & COPD

    Crowne Plaza Hotel - St James
    22nd April 2009
    London, United Kingdom

    Copthorne Tara Hotel

    Scarsdale Place
    Kensington
    London W8 5SR
    United Kingdom

    Copthorne Tara Hotel

    The Copthorne Tara Hotel London Kensington is an elegant contemporary four-star hotel in prestigious Kensington, located just a two minutes walk from High Street Kensington underground station, making exploring easy. The hotel offers well-appointed and comfortable guest rooms combining Standard, Superior and Club accommodation. Club rooms offer iconic views over the city and include Club Lounge access for complimentary breakfast and refreshments. Guests can sample the authentic Singaporean, Malaysian and Chinese cuisine at Bugis Street, traditional pub fare at the Brasserie Restaurant & Bar or relax with a delicious drink at West8 Cocktail Lounge & Bar.

    The Copthorne Tara Hotel boasts 745 square meters of flexible meeting space, consisting of the Shannon Suite and the Liffey Suite, ideal for hosting conferences, weddings and social events. Facilities include access to the business centre 24 hours a day, fully equipped fitness room, gift shop, theatre desk and Bureau de Change. With ample onsite parking outside the London congestion charge zone and excellent transport links via Heathrow Airport, the hotel is the perfect location for business or leisure stays. The hotel is within close proximity to the shops of High Street Kensington, Knightsbridge and Westfield London, Olympia Conference Centre, Royal Albert Hall, Kensington Palace and Hyde Park.

     

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.